Evidence map›Paper›PMID 27571206›Full record

ArticlePloS one2016

Distinct 3D Architecture and Dynamics of the Human HtrA2(Omi) Protease and Its Mutated Variants.

Artur Gieldon, Dorota Zurawa-Janicka, Miroslaw Jarzab, Tomasz Wenta, Przemyslaw Golik, Grzegorz Dubin, Barbara Lipinska, Jerzy Ciarkowski

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Identification and Characterization of an HtrA Sheddase Produced byInternational journal of molecular sciences · 2023
    Article
  2. Article
  3. Oligomeric assembly regulating mitochondrial HtrA2 function as examined by methyl-TROSY NMR.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Artur GieldonFaculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland.
Dorota Zurawa-JanickaDepartment of Biochemistry, Faculty of Biology, University of Gdansk, 80-308, Gdansk, Poland.
Miroslaw JarzabDepartment of Biochemistry, Faculty of Biology, University of Gdansk, 80-308, Gdansk, Poland.
Tomasz WentaDepartment of Biochemistry, Faculty of Biology, University of Gdansk, 80-308, Gdansk, Poland.
Przemyslaw GolikFaculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
Grzegorz DubinFaculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
Barbara LipinskaDepartment of Biochemistry, Faculty of Biology, University of Gdansk, 80-308, Gdansk, Poland.
Jerzy CiarkowskiFaculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland.
University of Gdańsk · PLJagiellonian University · PLMalopolska Higher Vocational School of J. Dietl in Kraków · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HtrA2(Omi) protease controls protein quality in mitochondria and plays a major role in apoptosis. Its HtrA2S306A mutant (with the catalytic serine routinely disabled for an X-ray study to avoid self-degradation) is a homotrimer whose subunits contain the serine protease domain (PD) and the regulatory PDZ domain. In the inactive state, a tight interdomain interface limits penetration of both PDZ-activating ligands and PD substrates into their respective target sites. We successfully crystalized HtrA2V226K/S306A, whose active counterpart HtrA2V226K has had higher proteolytic activity, suggesting higher propensity to opening the PD-PDZ interface than that of the wild type HtrA2. Yet, the crystal structure revealed the HtrA2V226K/S306A architecture typical of the inactive protein. To get a consistent interpretation of crystallographic data in the light of kinetic results, we employed molecular dynamics (MD). V325D inactivating mutant was used as a reference. Our simulations demonstrated that upon binding of a specific peptide ligand NH2-GWTMFWV-COOH, the PDZ domains open more dynamically in the wild type protease compared to the V226K mutant, whereas the movement is not observed in the V325D mutant. The movement relies on a PDZ vs. PD rotation which opens the PD-PDZ interface in a lid-like (budding flower-like in trimer) fashion. The noncovalent hinges A and B are provided by two clusters of interfacing residues, harboring V325D and V226K in the C- and N-terminal PD barrels, respectively. The opening of the subunit interfaces progresses in a sequential manner during the 50 ns MD simulation. In the systems without the ligand only minor PDZ shifts relative to PD are observed, but the interface does not open. Further activation-associated events, e.g. PDZ-L3 positional swap seen in any active HtrA protein (vs. HtrA2), were not observed. In summary, this study provides hints on the mechanism of activation of wtHtrA2, the dynamics of the inactive HtrA2V325D, but does not allow to explain an increased activity of HtrA2V226K.

Indexed as

Crystallography, X-RayHigh-Temperature Requirement A Serine Peptidase 2HumansMitochondrial ProteinsMolecular Dynamics SimulationMutationProtein Structure, SecondaryProtein Structure, TertiarySerine EndopeptidasesStructure-Activity RelationshipHigh-Temperature Requirement A Serine Peptidase 2HTRA2 protein, humanMitochondrial ProteinsSerine Endopeptidases

Identifiers

PMID27571206
PMCPMC5003398
OpenAlexW2518378049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.